Search

Displaying results 1361 - 1370 of 3733 in total
  1. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan).

    Categories: P-glycoprotein substrates, Thrombopoietin Receptor Agonist
  2. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

  3. Drug

    Norelgestromin

    go.drugbank.com/drugs/DB06713
    ApprovedInvestigational

    It is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Medium-chain triglycerides

    go.drugbank.com/drugs/DB13959
    ApprovedInvestigational

    Medium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms. MCTs are found in natural foods, such as coconut oil, palm kernel oil, and raw coc...

  5. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted f...

  6. Drug

    PF-06815345

    go.drugbank.com/drugs/DB14862
    Investigational

    PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in Healthy Subjects).

  7. Drug

    PRX-P4-003

    go.drugbank.com/drugs/DB33967
    Experimental

    PRX-P4-003 is a small molecule drug. … PRX-P4-003 is under investigation in clinical trial NCT04638803 (A Phase 0, Open-Label, Crossover Microdose Pharmacokinetic Study of PRX-P4-003 in Healthy Volunteers).

  8. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    Pibrentasvir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS5A inhibitor that targets the the viral RNA replication and viron assembly. In combination with DB13879, pibrentastiv is a useful therapy for patients who expe...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.

  10. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    [L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates